Photo taken from Grainne O’Kane/X
Jun 5, 2024, 13:27
Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24
Grainne O’Kane, Medical Oncologist and Clinical Research Fellow at Trinity St. James’s Cancer Institute, shared a post on X:
“GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.
- Important to remember most on PDAC trials less than 70 years.
- Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
- Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
- Need to identify who can benefit and discuss with patients.”
Source: Grainne O’Kane/X